Clinical, Dosimetric and Radiomic Features Predictive of Lung Toxicity After (Chemo)Radiotherapy
- PMID: 39672787
- DOI: 10.1016/j.cllc.2024.11.003
Clinical, Dosimetric and Radiomic Features Predictive of Lung Toxicity After (Chemo)Radiotherapy
Abstract
Background: Treatment of locally advanced non small cell lung cancer (LA-NSCLC) is based on (chemo)radiotherapy, which may cause acute lung toxicity: radiation pneumonitis (RP). Its frequency seems to increase by the use of adjuvant durvalumab therapy.
Aims: To identify clinical, dosimetric, and radiomic factors associated with grade (G)≥2 RP and build a prediction model based on selected parameters.
Patients and methods: This is a retrospective multicenter cohort study including patients receiving radiation therapy between 2015 and 2019 for LA-NSCLC. Baseline computed tomography scanners were segmented to extract radiomic features from the "Lung - Tumor" volume. Variables associated with the risk of G≥2 RP in the descriptive analysis were then selected for explanatory analysis, followed by predictive analysis.
Results: 153 patients were included in 4 centers (51 with G≥2 RP). Factors associated with G≥2 RP included a high initial hemoglobin level, dosimetric factors (mean dose to healthy lungs, lung V20Gy and V13Gy), the addition of maintenance durvalumab, and 7 radiomic features (intensity distribution and texture). Other factors were associated with an increased risk of G≥2 RP in our explanatory model, such as older age, low Tiffeneau ratio, and a decreased initial platelet count. The best-performing predictive model was a random forest-based learning model using clinical, dosimetric, and radiomic variables, with an area under the ROC curve of 0.72 (95%CI [0.63; 0.80]) versus 0.64 for models using one type of data.
Conclusion: The addition of radiomic features to clinical and dosimetric ones improves prediction of the occurrence of G≥2 RP in patients receiving radiotherapy for lung cancer.
Keywords: Artificial intelligence; Lung cancer; Radiation pneumonitis; Radiation therapy; Radiomics.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure Cécile Evin: Merck, Léo Razakamanantsoa : none, François Gardavaud: none, Léa Papillon: employed by SOPHiA GENETICS, Hamza Boulaala: employed by SOPHiA GENETICS, Loïc Ferrer: employed by SOPHiA GENETICS, Olivier Gallinato: employed by SOPHiA GENETICS, Thierry Colin: employed by SOPHiA GENETICS, Sondos Ben Moussa: none, Yara Harfouch: none, Jean-Noël Foulquier: none, Sophie Guillerm: none, Jean-Emmanuel Bibault: none, Florence Huguet : BMS, Merck, MSD, Amgen, Mathilde Wagner: none, Eleonor Rivin del Campo: none.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
